News
AGYTF
0.110
NaN%
--
Allergy Therapeutics boosts funding as Grassmuno launch and peanut vaccine advance
TipRanks · 03/31 07:12
Allergy Therapeutics Reshapes Major Shareholding Ahead of Potential Hong Kong Listing
TipRanks · 03/12 07:10
Allergy Therapeutics’ VLP Peanut Shows Strong Immune Response in Early-Stage Trial
TipRanks · 03/04 07:18
Allergy Therapeutics showcases new allergy immunotherapy data at AAAAI 2026
TipRanks · 02/26 07:22
Allergy Therapeutics seals £40m Hayfin facility and simplifies capital structure
TipRanks · 02/23 07:58
Allergy Therapeutics Bolsters Board and Strategy Team to Drive Global Expansion
TipRanks · 01/30 08:53
Allergy Therapeutics Wins Strong Shareholder Backing at 2026 AGM
TipRanks · 01/29 14:37
Allergy Therapeutics Grants Performance-Linked Share Options to Senior Management
TipRanks · 01/28 16:52
Allergy Therapeutics lifts revenues and launches Grassmuno as German TAV transition accelerates
TipRanks · 01/19 07:11
Allergy Therapeutics Adds Asia-Focused Expertise to Board Ahead of Potential Hong Kong Listing
TipRanks · 01/06 07:08
Allergy Therapeutics Wins Shareholder Mandate for Potential Equity Raise Ahead of Hong Kong Dual Listing
TipRanks · 12/29/2025 13:12
Allergy Therapeutics Secures German Approval for Grassmuno® Immunotherapy
TipRanks · 12/16/2025 07:09
Allergy Therapeutics Gains German Approval for Grassmuno Immunotherapy
TipRanks · 12/16/2025 07:08
Allergy Therapeutics Plans Potential Equity Raise Ahead of Hong Kong Listing
TipRanks · 12/12/2025 07:14
Allergy Therapeutics Reports Stable Financials and Strategic Growth Initiatives
TipRanks · 12/11/2025 07:09
Allergy Therapeutics Achieves Key Milestone in Peanut Allergy Treatment Trial
TipRanks · 12/09/2025 07:08
Allergy Therapeutics Considers Dual Listing on HKEX to Expand Asian Market Presence
TipRanks · 11/06/2025 08:31
Allergy Therapeutics Advances Phase III Trial for Paediatric Grass Allergy Treatment
TipRanks · 10/30/2025 07:42
Allergy Therapeutics Strengthens Financial Position with New Loan Facility
TipRanks · 10/29/2025 07:15
Allergy Therapeutics Advances Peanut Allergy Vaccine with Positive Trial Results
TipRanks · 10/16/2025 06:10
More
Webull provides a variety of real-time AGYTF stock news. You can receive the latest news about Allergy Ther through multiple platforms. This information may help you make smarter investment decisions.
About AGYTF
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.